<DOC>
	<DOCNO>NCT00336492</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety infliximab ( Remicade ) child moderately severely active ulcerative colitis .</brief_summary>
	<brief_title>A Study Safety Efficacy Infliximab ( REMICADE ) Pediatric Patients With Moderately SeverelyActive Ulcerative Colitis</brief_title>
	<detailed_description>Ulcerative Colitis ( UC ) disorder involve line colon . A substance call `` tumor necrosis factor '' ( TNF ) naturally occur body . TNF think play important role development ulcerative colitis cause damage see colon . `` Antibodies '' normally make body help fight infection . Infliximab antibody make scientific laboratory , use part mouse human antibody . It design attach TNF , make difficult TNF damage . This study do center North America Europe . Each child first clinic visit ( screen visit ) test do make sure child type patient study . At 2nd visit ( week 0 ) , child first treatment infliximab . All child study receive 5 mg/kg infliximab 3 time ( week 0 , 2 6 ) first 6 week study . If child 's symptom improve 8th week , child receive infusion , return safety evaluation . If child 's symptom improve , child randomly assign ( like flip coin ) either 5 mg/kg infliximab every 8 week week 46 5 mg/kg infliximab every 12 week week 42 . If child get bad randomly assign , amount infliximab may increase infliximab may give frequently . A final infusion give either week 42 week 46 . There safety evaluation week 54 visit week 62 get blood sample . Patients receive 5 mg/kg infliximab week 0 , 2 6 5mg/kg infliximab either every 8 week 12 week week 42 46 . Infliximab give intravenous infusion 2 hour .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Have moderately severely active ulcerative colitis Diagnosed ulcerative colitis 2 week screen Male patient sexually active female patient sexually active childbearing potential must use adequate birth control participation study 6 month last infusion . History latent active TB Have live viral bacterial vaccination within 3 month screen Have serious infection within 3 month screen Prior treatment infliximab</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Ulcerative colitis</keyword>
	<keyword>inflammatory bowel disease</keyword>
	<keyword>child</keyword>
</DOC>